cancerous area News
-
Synaffix Announces $1 Billion Deal Expansion with Mersana
Expanded deal focuses on Synaffix’s GlycoConnect™ site-specific ADC bioconjugation technology and adds license options for six new programs to existing deal Mersana currently developing two programs based on GlycoConnect™ site-specific ADC bioconjugation technology (XMT-1592 and XMT-1660) Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage ...
By Synaffix BV
-
Cancer risk from bad Southern California air eases
Southern California's air is getting healthier, and with that the chances of getting cancer from inhaling toxins has fallen significantly. The risk of cancer from airborne pollutants has dropped by more than 50 percent on average since 2005, according to a study released Thursday by the region's air quality regulators. Concerted efforts to reduce emissions from diesel trucks and other vehicles ...
-
Chrysalis BioTherapeutics Receives BARDA Contract for Over $10 million
Chrysalis BioTherapeutics, Inc. today announced that the Biomedical Advanced Research and Development Authority (BARDA), an agency of the US government’s Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, has awarded Chrysalis a contract (HHSO100201900016C) to support the continued development of TP508, rusalatide acetate, as a ...
-
Dyve Biosciences Announces Research and Development Collaboration with Moffitt Cancer Center
CAMARILLO, Calif. and TAMPA, Fla., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company applying its proprietary transdermal delivery technology to a broad pipeline of clinical assets, today announced a joint, two-year research collaboration with Moffitt Cancer Center. The collaboration will study Dyve’s systemic buffering agent, ...
-
Mersana Therapeutics Announces Research Collaboration and License Agreement with Janssen to Advance Novel Antibody-Drug Conjugates
Collaboration focused on discovering novel ADCs for three targets by leveraging Mersana’s ADC expertise and the Dolasynthen platform with Janssen’s proprietary antibodies Mersana receives $40 million upfront payment and potentially more than $1 billion in total milestones, plus mid-single-digit to low double-digit percentage royalties on net sales CAMBRIDGE, Mass., Feb. 03, ...
-
BTG Specialty Pharmaceuticals advances global regulatory program for glucarpidase, sold as Voraxaze in the US
BTG Specialty Pharmaceuticals announced that Ohara Pharmaceutical Co., Ltd. has obtained marketing authorization for glucarpidase from Japan's Ministry of Health, Labour and Welfare as a therapeutic agent for “detoxication in case of delayed methotrexate elimination with methotrexate-leucovorin rescue therapy,” on September 27, 2021. Ohara will sell glucarpidase in Japan with the ...
-
Mersana Therapeutics to Present an Analysis from the Expansion Cohort of the Phase 1 Trial of Upifitamab Rilsodotin at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer
CAMBRIDGE, Mass., March 15, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will present an analysis based on the June 10th, 2021 data cut from the expansion cohort of the ...
-
Dorian Therapeutics Accesses Novel Compound Library from Ubiquigent
Ubiquigent Limited, a company focused on enabling and supporting ubiquitin system-focused drug discovery, announced today that it had entered into an agreement with Dorian Therapeutics to provide access to one of its novel small molecule libraries specifically designed to target deubiquitylase (DUB) enzymes. “We hope that this is just the beginning of a fruitful partnership, and that ...
-
Elsevier Foundation announces 2010 grants for libraries in developing countries
The Elsevier Foundation has announced the 2010 recipients of grants under its Innovative Libraries in Developing Countries program, committing over $300,000 to support the work of libraries in developing countries. The 2010 grant recipients were selected from 260 proposals worldwide for their innovation and potential for impact in the developing world. The Innovative Libraries program supports ...
-
Dako, an Agilent Technologies Company, Announces FDA Approval of New Test for Lung Cancer Patients
Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, today announced the U.S. Food and Drug Administration has approved a new test that can identify PD-L1 expression levels on the surface of non-small cell lung cancer tumor cells and provide information on the survival benefit with OPDIVO® (nivolumab) for patients with non-squamous NSCLC. Dako developed the ...
-
Mersana Therapeutics Announces FDA Grant of Orphan Drug Designation to XMT-2056 for the Treatment of Gastric Cancer
CAMBRIDGE, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to XMT-2056, the ...
-
Seattle AVM Biotechnology announces second IND for AVM0703: clinical trial permitted to treat COVID-19 and Influenza ARDS with its “supercharged” version of dexamethasone
AVM Biotechnology has received FDA permission to proceed with clinical trials to evaluate its proprietary drug AVM0703 in the treatment of Acute Respiratory Distress Syndrome (ARDS) mediated by COVID-19 or Influenza patients. This is AVM’s second “safe to proceed” clinical trial authorization from the FDA within the past six months and demonstrates the broad potential of ...
-
Prellis Biologics Launches In Vitro Human Antibody Discovery Platform, Announces $14.5 Million Series B Investment, Key Executive Hires
Prellis Biologics announced today that it has closed a $14.5 million Series B financing round, led by Celesta Capital and current investor Khosla Ventures Prellis will use the proceeds to advance its Externalized Immune System (EXIS™) platform, a first-in-class in vitro, fully human antibody discovery, and vaccine screening workflow. “The EXIS platform offers unprecedented in vitro ...
-
Prellis Biologics Launches In Vitro Human Antibody Discovery Platform, Announces $14.5 Million Series B Investment, Key Executive Hires
Prellis Biologics announced today that it has closed a $14.5 million Series B financing round, led by Celesta Capital and current investor Khosla Ventures Prellis will use the proceeds to advance its Externalized Immune System (EXIS™) platform, a first-in-class in vitro, fully human antibody discovery, and vaccine screening workflow. “The EXIS platform offers unprecedented in vitro ...
-
Dexamethasone reportedly part of President Trump’s Treatment
As part of the standard of care treatment protocol, President Trump received dexamethasone for his COVID-19 disease, highlighting the value of dexamethasone. Dexamethasone has been widely used since its initial approval in 1958 in treating acute disease. The use of higher dexamethasone doses, with potentially additional and desired immunological effects, is limited due the presence of toxic ...
-
Surgeon Explains the Importance of Preserving the Breast During Cancer Treatment through Education, the Latest Technology—and an Artistic Touch
Dr. Elizabeth Revesz has a unique background as an artist and sculptor. She was able to translate her precision, and her ability to see things in three dimensions, into a highly successful career in medicine. But once in the medical field, Dr. Revesz went further to find her true calling. “Medicine is great, but surgery is actually where I feel the most comfortable,” the physician ...
-
Infection transmission prevention and control of Coronavirus (COVID-19) made possible through Genano Air Decontamination Units
Infection control procedures including work practices, protocols and controls, environmental hygiene, air filtration and appropriate use of Personal Protective Equipment (PPE) are all necessary to prevent infections from spreading during healthcare service delivery. But in the case of the recent Coronavirus (COVID-19) outbreak early detection and isolation of potentially infectious patients is ...
-
Discover our top-selling Precellys kits!
For many years, scientists all around the globe have been using Precellys lysing and grinding kits, as they have been proven efficient and safe in a broad range of research areas including microbiology, pharmacology, cancer, forensic medicine, the environment, and even agronomy. Here below, discover our top three bestselling kits and find the perfect solution for your sample prep! ...
-
Icecure Medical Receives Notice of Intention to Grant a European Patent Covering its Cryogenic Pump
IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it received notification from the European Patent Office (the “EPO”) of an intention to grant a patent ...
-
CASELLA CHOOSES CANCER RESEARCH UK AS CHARITY PARTNER
As Casella Measurement launches its new Corporate Social Responsibility (CSR) Policy, it is particularly apt that the specialist in occupational health and environmental monitoring equipment has chosen Cancer Research UK as its charity partner, since use of the company’s dust measuring devices play an important part in the fight against lung cancer. The link with the charity is also seen ...
By Casella
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you